Hims & Hers Lifts 2026 Revenue Forecast on Strong Demand for Personalized Care

• The company now projects 2026 annual revenue of $2.8-$3 billion, up from its previous forecast of $2.7-$2.9 billion
• Second-quarter revenue is expected at $680-$700 million, significantly above analyst estimates of $642.95 million
• Hims partnered with Novo Nordisk in March to offer Wegovy, ending litigation and discontinuing its low-cost compounded alternative to the blockbuster weight-loss drug

Summary

Hims & Hers Health Raises 2026 Revenue Outlook on Personalized Healthcare Demand

Hims & Hers Health has increased its 2026 revenue forecast to $2.8-3.0 billion, up from the previous range of $2.7-2.9 billion, driven by strong demand for its personalized healthcare services.

Key Developments:

The telehealth company announced on May 11 that it now expects second-quarter 2026 revenue between $680-700 million, significantly exceeding analyst estimates of $642.95 million according to LSEG data.

Strategic Partnership:

In March, Hims reached a landmark agreement with Novo Nordisk to offer Wegovy, the pharmaceutical giant's blockbuster weight-loss drug, on its platform. This partnership resolved an ongoing legal dispute between the two companies that arose after Hims launched a low-cost compounded alternative to Wegovy, which has since been discontinued.

Market Implications:

The raised guidance signals robust growth momentum in the direct-to-consumer telehealth sector, particularly for personalized care solutions. The Novo Nordisk partnership positions Hims to capitalize on surging demand for GLP-1 weight-loss medications while eliminating regulatory and legal risks associated with compounded alternatives.

The Q2 revenue guidance beating analyst expectations by approximately 6-9% suggests accelerating business momentum and strong customer acquisition. This development underscores the growing mainstream acceptance of telehealth platforms and the significant market opportunity in weight management solutions.

Sector: Telehealth/Digital Healthcare

Companies: Hims & Hers Health, Novo Nordisk

The partnership and improved outlook reflect Hims' successful transition from controversial compounded drugs to legitimate pharmaceutical partnerships, potentially strengthening its competitive position in the expanding digital health market.